Sanofi (NASDAQ:SNY) Shares Purchased by China Universal Asset Management Co. Ltd.

China Universal Asset Management Co. Ltd. grew its holdings in Sanofi (NASDAQ:SNY) by 69.9% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 56,230 shares of the company’s stock after acquiring an additional 23,138 shares during the period. China Universal Asset Management Co. Ltd.’s holdings in Sanofi were worth $3,241,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also made changes to their positions in SNY. Stablepoint Partners LLC boosted its holdings in shares of Sanofi by 0.8% in the 3rd quarter. Stablepoint Partners LLC now owns 23,893 shares of the company’s stock valued at $1,377,000 after buying an additional 189 shares in the last quarter. Eagle Ridge Investment Management raised its stake in Sanofi by 3.8% in the 3rd quarter. Eagle Ridge Investment Management now owns 5,571 shares of the company’s stock valued at $321,000 after purchasing an additional 203 shares during the last quarter. TCTC Holdings LLC lifted its stake in shares of Sanofi by 28.0% during the 1st quarter. TCTC Holdings LLC now owns 960 shares of the company’s stock worth $47,000 after purchasing an additional 210 shares during the period. HB Wealth Management LLC grew its holdings in Sanofi by 3.7% in the second quarter. HB Wealth Management LLC now owns 6,166 shares of the company’s stock valued at $299,000 after purchasing an additional 221 shares during the period. Finally, Insigneo Advisory Services LLC increased its stake in Sanofi by 3.3% during the second quarter. Insigneo Advisory Services LLC now owns 7,212 shares of the company’s stock worth $371,000 after acquiring an additional 228 shares during the last quarter. 10.04% of the stock is owned by institutional investors and hedge funds.

Sanofi Stock Up 0.0 %

Shares of Sanofi stock opened at $54.36 on Tuesday. Sanofi has a 1 year low of $44.05 and a 1 year high of $58.97. The company has a market cap of $137.96 billion, a P/E ratio of 27.73, a P/E/G ratio of 1.55 and a beta of 0.60. The company has a current ratio of 1.00, a quick ratio of 0.65 and a debt-to-equity ratio of 0.17. The stock has a 50-day moving average price of $56.08 and a 200 day moving average price of $51.84.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings results on Friday, October 25th. The company reported $1.57 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.22 by $1.35. Sanofi had a net margin of 9.96% and a return on equity of 20.59%. The business had revenue of $13.44 billion during the quarter, compared to analyst estimates of $16.59 billion. During the same period in the prior year, the firm earned $2.55 earnings per share. The firm’s revenue was up 12.3% compared to the same quarter last year. As a group, analysts expect that Sanofi will post 4.25 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

SNY has been the subject of a number of analyst reports. StockNews.com cut Sanofi from a “strong-buy” rating to a “buy” rating in a report on Monday, October 14th. Argus boosted their target price on shares of Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a research note on Friday, July 26th. Finally, Citigroup upgraded shares of Sanofi to a “strong-buy” rating in a report on Tuesday, September 17th. Three analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $57.50.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.